Literature DB >> 30377024

Melatonin treatment in fetal and neonatal diseases.

Fernanda Rodrigues Helmo1, Renata Margarida Etchebehere2, Natália Bernardes1, Maria Flávia Meirelles1, Caetano Galvão Petrini3, Laura Penna Rocha1, Maria Luíza Gonçalves Dos Reis Monteiro1, Camila Souza de Oliveira Guimarães4, Vicente de Paula Antunes Teixeira1, Marlene Antônia Dos Reis1, Juliana Reis Machado1, Rosana Rosa Miranda Corrêa5.   

Abstract

This literature review aims to address the main scientific findings on oxidative stress activity in different gestational disorders, as well as the function and application of melatonin in the treatment of fetal and neonatal changes. Oxidative stress has been associated with the etiopathogenesis of recurrent miscarriages, preeclampsia, intrauterine growth restriction, and stillbirth. Both, the exacerbated consumption of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase, and the increased synthesis of reactive oxygen species, such as superoxide, peroxynitrite, and hydrogen peroxide, induce phospholipid peroxidation and endothelial dysfunction, impaired invasion and death of trophoblast cells, impaired decidualization, and remodeling of maternal spiral arteries. It has been postulated that melatonin induces specific biochemical responses that regulate cell proliferation in fetuses, and that its antioxidant action promotes bioavailability of nitric oxide and, thus, placental perfusion and also fetal nutrition and oxygenation. Therefore, the therapeutic action of melatonin has been the subject of major studies that aim to minimize or prevent different injuries affecting this pediatric age group, such as intrauterine growth restriction, encephalopathy, chronic lung diseases, retinopathy of prematurity
Conclusion: the results antioxidant and indicate that melatonin is an important therapy for the clinical treatment of these diseases.
Copyright © 2018. Published by Elsevier GmbH.

Entities:  

Keywords:  Fetal disease; Melatonin; Neonatal disease; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 30377024     DOI: 10.1016/j.prp.2018.10.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

Review 1.  Effects of Antioxidant Intake on Fetal Development and Maternal/Neonatal Health during Pregnancy.

Authors:  Giorgia Sebastiani; Elisabet Navarro-Tapia; Laura Almeida-Toledano; Mariona Serra-Delgado; Anna Lucia Paltrinieri; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Antioxidants (Basel)       Date:  2022-03-28

2.  Impact of Melatonin on Full-Term Fetal Brain Development and Transforming Growth Factor-β Level in a Rat Model of Preeclampsia.

Authors:  Nanees Fouad El-Malkey; Mohammed Aref; Hassan Emam; Sama Salah Khalil
Journal:  Reprod Sci       Date:  2021-02-16       Impact factor: 3.060

3.  Melatonin ameliorates necrotizing enterocolitis by preventing Th17/Treg imbalance through activation of the AMPK/SIRT1 pathway.

Authors:  Fei Ma; Hu Hao; Xiaoyan Gao; Yao Cai; Jialiang Zhou; Puping Liang; Junjian Lv; Qiuming He; Congcong Shi; Dandan Hu; Bowei Chen; Lixin Zhu; Xin Xiao; Sitao Li
Journal:  Theranostics       Date:  2020-06-19       Impact factor: 11.556

Review 4.  Perinatal Use of Melatonin for Offspring Health: Focus on Cardiovascular and Neurological Diseases.

Authors:  Chien-Ning Hsu; Li-Tung Huang; You-Lin Tain
Journal:  Int J Mol Sci       Date:  2019-11-13       Impact factor: 5.923

Review 5.  Maternal Melatonin Deficiency Leads to Endocrine Pathologies in Children in Early Ontogenesis.

Authors:  Dmitry O Ivanov; Inna I Evsyukova; Ekaterina S Mironova; Victoria O Polyakova; Igor M Kvetnoy; Ruslan A Nasyrov
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.